The generic name for Lorbrena is lorlatinib [1].
What is lorlatinib used to treat?
Lorlatinib is a prescription medication used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to other parts of the body [1]. Specifically, it is indicated for patients whose tumors have a specific genetic mutation, an anaplastic lymphoma kinase (ALK) or ROS1 (anaplastic lymphoma kinase) gene fusion [1]. It is used for both newly diagnosed patients and those whose cancer has progressed after other ALK-targeted treatments [1].
How does lorlatinib work?
Lorlatinib is an ALK inhibitor that works by blocking the activity of the ALK and ROS1 proteins. These proteins can promote cancer cell growth when they are altered by gene fusions [1]. By inhibiting these proteins, lorlatinib helps to slow down or stop the growth of cancer cells [1].
What are the potential side effects of lorlatinib?
Common side effects of lorlatinib can include high cholesterol, swelling, peripheral neuropathy (nerve problems), fatigue, and cognitive effects [1]. Serious side effects may include central nervous system effects, such as changes in mood, thoughts, and behavior, and severe skin reactions [1]. It is important for patients to discuss any side effects with their healthcare provider [1].
When did lorlatinib receive FDA approval?
Lorlatinib was first approved by the U.S. Food and Drug Administration (FDA) in November 2017 [1].
What is the difference between lorlatinib and other ALK inhibitors?
Lorlatinib is a third-generation ALK inhibitor. It was designed to be effective against a broader range of ALK resistance mutations that can develop after treatment with earlier ALK inhibitors [1]. It also has a greater ability to penetrate the blood-brain barrier, making it effective for brain metastases [1].
Who manufactures lorlatinib?
Lorlatinib is manufactured by Pfizer [1].
What is the cost of lorlatinib?
The cost of lorlatinib can vary significantly depending on insurance coverage, pharmacy, and dosage [2]. Information from online sources suggests that a 30-day supply can range from approximately $11,000 to $13,000 [2]. Patient assistance programs may be available through the manufacturer to help reduce out-of-pocket costs [3].
What are the clinical trial results for lorlatinib?
Clinical trials have demonstrated the efficacy of lorlatinib in patients with ALK-positive NSCLC [1]. For instance, in the CROWN study, lorlatinib showed significant improvement in progression-free survival compared to crizotinib in newly diagnosed patients with ALK-positive metastatic NSCLC [4]. It also demonstrated efficacy in patients who had previously been treated with other ALK inhibitors [1][4].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-atomoxetine-lorlatinib
[2] https://www.goodrx.com/lorlatinib
[3] https://www.pfizerpro.com/products/lorlatinib
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2209577